Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board Tubulis today announced the appointment of Dr. Christian Grøndahl, as the inaugural Chairman of the company s Supervisory Board. As an experienced biotech executive and company founder, Dr. Grøndahl has an established track record in advancing early-stage biotech innovations and distinguished technology platforms into valuable products and medicines. His leadership will be fundamental to shaping Tubulis as it designs and moves its novel antibody-drug conjugates (ADCs) toward clinical evaluation to improve cancer treatments and further establishes itself as an up-and-coming leader in the oncology and ADC drug development field.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel .
AKAMPIONApril 12, 2021 GMT
- Company forms international consortium with ProteoGenix SAS and Amsterdam UMC
Schlieren (Zurich Area), Switzerland – April 12, 2021 – ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands).
Alentis Therapeutics: Alentis Founder Receives Prestigious French Academy of Science Award
Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Prof. Thomas Baumert, its founder and world-leading authority in the field, has been awarded the Mémain-Pelletier, French Academy of Science award for his ground-breaking research into understanding the pathogenesis of liver cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201222005253/en/
Professor Thomas Baumert, founder of Alentis Therapeutics. Copyright Alentis Therapeutics
Said Prof. Thomas Baumert: It s a great honor and a mark of recognition for my team, my colleagues and collaborators, some 50 in all. Now we are going to have to redouble our efforts, with a view to bringing our research to patients so they can truly benefit.
Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Prof. Thomas Baumert, its founder and world-leading authority in the field, has been awarded the Mémain-Pelletier, French Academy of Science award for his ground-breaking research into understanding the pathogenesis of liver cancer.
Professor Thomas Baumert, founder of Alentis Therapeutics. Copyright Alentis Therapeutics
Said Prof. Thomas Baumert: “It’s a great honor and a mark of recognition for my team, my colleagues and collaborators, some 50 in all. Now we are going to have to redouble our efforts, with a view to bringing our research to patients so they can truly benefit.”